However, there were "immortal cells" buried within us all, so-called stem cells that could replicate forever, unchanged. They were present at the very beginning of life and all our differing body tissue was created from them. Some still lingered on in our body, as though to be available for spare parts. If one could figure out how to transfer the characteristics of those cells to other cells, then the possibility existed that we could regenerate damaged or aging tissue in our vital organs. The trick was to figure out the mechanism whereby stem cells managed to cheat time. His research, which was accompanied by a flurry of scientific papers, was celebrated and encouraging. After three years he was lured away from Yale to become a faculty member at Johns Hopkins, which offered to double his laboratory budget. He was there for six years, during which time he met Camille Buseine, a neurosurgeon finishing her residency. She had a doctorate from a medical institute near Paris and she was doing research that was similar to his, so the biography said. They married and became a team, and when he was asked by Harvard Medical to found a department for molecular genetics, she was immediately offered a tenured position there too. Harvard considered it a double coup. His research was zeroing in on the telomerase protein, an enzyme many scientists believed was responsible for suppressing the aging process in stem cells. Could it be used to regenerate tissue? He was well along on the task of exploring that tantalizing possibility when tragedy struck. Camille, who had worked around the clock during her residency at Johns Hopkins, began feeling weak at Harvard and was diagnosed with acquired aortic stenosis. After a 2 1/2-year struggle, she died during a severe cardiac episode. My God, Ally thought, that's what I have. After Camille died, he left Harvard and its time-consuming academic obligations and went to work full-time at a research institute affiliated with Stanford University. He even formed a paper company to structure the work, the Gerex Corporation. But then there came a second strike against him. He was doing research using embryonic stem cells obtained from the discarded embryos at fertility clinics. After two years of harassment by right-wing political groups, Stanford decided his research was too controversial and terminated his funding. Three months later, Karl Van de Vliet merged his company with Bartlett Medical Devices and moved his research staff east to New Jersey, to the Dorian Institute. That was five years past, and now his research using stem cells was in third-stage NIH clinical trials. The official history ended there, though with a strong hint that the final chapter was yet to be written. Then at the back there was a bibliography of publications that extended for eight pages, and included a summary of the most important papers. His work on stem cells and the telomerase enzyme appeared to be at the forefront of the field.